Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildacerfont in children with congenital adrenal hyperplasia
NCT05128942Phase 2Terminated
- Sponsor
- Spruce Biosciences, Inc.
- Start
- Dec 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tildacerfont in congenital adrenal hyperplasia (CAH) (9 cohorts), sponsored by Spruce Biosciences, Inc. Primary endpoint: Treatment-emergent Adverse Event at 12 weeks. Started Dec 2021; status: terminated.
02
Drugs
tildacerfont
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT05128942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128942.